{"id":"W2732548543","doi":"10.1111/bjh.14787","title":"Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <scp>ELOQUENT</scp>‐2 follow‐up and <i>post‐hoc</i> analyses on progression‐free survival and tumour growth","year":2017,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"AbbVie Biotherapeutics; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Dexamethasone; Hazard ratio; Internal medicine; Multiple myeloma; Progression-free survival; Post-hoc analysis; Oncology; Interim analysis; Refractory (planetary science); Gastroenterology; Surgery; Chemotherapy; Randomized controlled trial; Confidence interval; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001008285,0.0003674384,0.001611906,0.0003378125,0.0007334377,0.0002560825,0.0004365265,0.0002874579,0.00002539227],"category_scores_gemma":[0.01704969,0.0002928939,0.0002977821,0.00009734171,0.0005726583,0.0003812263,0.000239116,0.0006361133,0.000005712171],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001363767,"about_ca_system_score_gemma":0.0005034042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004890104,"about_ca_topic_score_gemma":0.0006638705,"domain_scores_codex":[0.9967931,0.0003452893,0.0008721928,0.000528861,0.0007165252,0.0007440685],"domain_scores_gemma":[0.9945766,0.002389706,0.001025442,0.000490163,0.0007899368,0.0007281349],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"observational","study_design_scores_codex":[0.06769958,0.005080066,0.1752739,0.004013515,0.009964434,0.4149601,0.002024928,0.000003505467,0.02992337,0.001121081,0.04955285,0.2403826],"study_design_scores_gemma":[0.1823383,0.01778441,0.4936201,0.004945728,0.001621446,0.2752002,0.002232851,0.0003370611,0.01655051,0.001275623,0.003554181,0.0005395567],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886025,0.008266667,0.0001445246,0.0009546297,0.0004736143,0.0009424997,0.0001400413,0.00003174447,0.0004437709],"genre_scores_gemma":[0.9908447,0.002581998,0.005062848,0.0001304277,0.0002234086,0.00006949802,0.00003308071,0.00007108247,0.0009829914],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3183462,"threshold_uncertainty_score":0.9999523,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07180174197422885,"score_gpt":0.3709442577312493,"score_spread":0.2991425157570205,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}